Genmab (GMAB)
Quick facts
| Ticker | GMAB (NASDAQ) |
|---|
Phase 3 pipeline
- Investigator's Choice Chemotherapy · Oncology
Investigator's Choice Chemotherapy refers to a flexible treatment approach where the investigating physician selects from approved chemotherapy regimens based on patient and tumor characteristics. - Rina-S · Oncology
Rina-S is a bispecific antibody that simultaneously engages two immune checkpoints to enhance T-cell activation and anti-tumor immunity.
Phase 2 pipeline
- CC-99282
- Doxorubicin Hydrochloride [HCl] · Oncology
Topoisomerase II inhibitor
Phase 1 pipeline
- GEN1042
- GEN1056
- GEN1057
- GEN1079
- GEN1106
- GEN1286
- GEN3018
- rituximab, ifosfamide, carboplatin, and etoposide phosphate
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Genmab
What is the ticker symbol for Genmab?
Genmab trades as GMAB on the NASDAQ.
What is Genmab's pipeline?
Genmab has 2 drugs in Phase 3, 2 in Phase 2, 8 in Phase 1. Late-stage candidates include Investigator's Choice Chemotherapy, Rina-S.
How many employees does Genmab have?
Genmab has approximately 3,088 employees.
Related
- Sector hub: All tracked pharma companies
- Ticker: GMAB · NASDAQ